$CSBR

CHAMPIONS ONCOLOGY, INC. (CSBR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Tel: 551-206-8104 Champions Oncology Reports Revenue of $15.2 Million Oncology services margin improves to 51%; Adjusted EBITDA increases to $671,000 Hackensack, NJ – September 10 , 2026 – Champions Oncology,

Champions Oncology (CSBR) reported Q1 FY2027 revenue of $15.2M, up 8.8% YoY. Oncology services margin improved to 51% from 43%, and adjusted EBITDA increased to $671K from $59K. The company invested in commercial organization and growth initiatives, with net loss narrowing to $426K from $466K.

Several major companies, including Oracle, Adobe, and Copart, are set to report earnings on Thursday. Estimates for Oracle include EPS of $1.73 and revenue of $19.13B. Other companies reporting include Macy's, Restoration Hardware, and more, covering sectors like software, retail, and automotive services.

CHAMPIONS ONCOLOGY, INC. (CSBR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 csbr8-k4302026exhibit991.htm EX-99.1 Document Exhibit 99.1 NEWS One University Plaza, Suite 307 Hackensack, NJ 07601 Champions Oncology Reports Record Annual Revenue of $59 Million Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA Hackensack, NJ – July 27,

Champions Oncology (NASDAQ:CSBR) recently traded below its 200-day moving average, reaching $5.90, significantly lower than its $6.46 average. Analyst sentiment is bearish, with a "Sell" consensus rating from MarketBeat and a downgrade from Weiss Ratings. Institutional ownership is notable at 41.3%, though mixed, as several funds recently adjusted their positions in the company, which has an $86 million market cap and a negative P/E ratio.

Champions Oncology, Inc. reported third-quarter fiscal 2026 revenue of $16.6 million, a 2.8% decline year-over-year, largely due to the absence of a $4.5 million data license transaction present in the prior year. The company posted a net loss of $279,000 for the quarter and adjusted EBITDA of $574,000. Despite trading near its 52-week low, InvestingPro analysis suggests the stock is currently overvalued.

Champions Oncology (NASDAQ: CSBR) reported a Q3 fiscal 2026 revenue of $16.6 million, a 2.8% decline year-over-year, primarily due to the absence of a large data license transaction from the prior year. Despite a 32% increase in study service revenue, the company posted a net loss of $279,000 and adjusted EBITDA of $574,000, significantly lower than the previous year. Costs also rose, but the company finished the quarter with $7.1 million in cash and no debt.

Champions Oncology, Inc. announced its financial results for the third quarter of fiscal 2026, reporting revenue of $16.6 million. The company is on track to deliver year-over-year revenue growth and positive adjusted EBITDA for the fiscal year, despite a slight decrease in total revenue compared to the prior year period due to the absence of a large data license transaction. Study service revenue increased by 32% year-over-year, reflecting strong study execution and conversion of previously booked work.

Champions Oncology, Inc. (CSBR) will report its financial and operational results for the second quarter ended October 31, 2025, on Monday, December 15, 2025, after market close. The company will host a conference call to discuss these results on the same day at 4:30 P.M. EST. Champions Oncology is a leading translational oncology research organization offering end-to-end oncology R&D solutions to biopharma organizations.

Several biotech stocks have seen their strength fade over the past week, with their Momentum scores in Benzinga's Edge Stock Rankings witnessing a significant decline.